^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR L833V + EGFR H835L

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    20d
    Clinical Response to Osimertinib in a Non-Small-Cell Lung Cancer Patient With EGFR L833V/H835L Mutations: A Case Report. (PubMed, J Investig Med High Impact Case Rep)
    This case demonstrates the efficacy of osimertinib for rare EGFR mutations, aligning with literature suggesting its potential for managing such variants. Although large-scale trials are impractical due to the rarity of these mutations, this report adds valuable evidence supporting osimertinib's use, highlighting the need for comprehensive genomic profiling in NSCLC.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L833V + EGFR H835L • EGFR L858R + EGFR exon 19 deletion
    |
    Tagrisso (osimertinib)
    1year
    A Rare Case of Lung Adenocarcinoma with EGFR L833V/H835L Co-mutation and Literature Review (PubMed, Zhongguo Fei Ai Za Zhi)
    In this article, we reported a case of NSCLC patient with a rare gene compound mutation EGFR L833V/H835L, who responded to Afatinib in combination with Anilotinib treatment well after 5 months of treatment, and computed tomography (CT) showed shrinkage of lung lesions. Meanwhile, we also compiled previously reported NSCLC patients with EGFR L833V/H835L rare gene compound mutation and summarized the characteristics of this group of patients and the effect of applying different kinds of EGFR-TKIs treatment..
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 18 mutation • EGFR L833V + EGFR H835L • EGFR H835L • EGFR L833V
    |
    Gilotrif (afatinib)
    over1year
    Complete response to first-line osimertinib monotherapy in a complex epidermal growth factor receptor mutant (L833V/H835L) lung adenocarcinoma patient: a case report. (PubMed, Anticancer Drugs)
    The patient remain benefitted for osimertinib monotherapy over 22 months with no disease progression. Our case firstly provided clinical evidences of first-line osimertinib therapy in lung cancer patients with rare L833V/H835L EGFR mutation.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    EGFR mutation • EGFR L833V + EGFR H835L • EGFR H835L • EGFR L833V
    |
    Tagrisso (osimertinib)